2. Signaling Pathways
  3. Immunology/Inflammation
  4. FAP

FAP

Fibroblast activation protein

Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-161262
    SB03178
    		Inhibitor
    SB03178 is a fibroblast activation protein-alpha (FAP) inhibitor. SB03178 can be conjugated with DOTA and can be used for cancer research.
    SB03178
  • HY-149860
    FAP-IN-1
    		Inhibitor
    FAP-IN-1 is a fibroblast activation protein (FAP) inhibitor with an IC50 value of 3.3 nM. FAP-IN-1 can be used for the research of cancer.
    FAP-IN-1
  • HY-146180
    FSDD0I
    FSDD0I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD0I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
    FSDD0I
  • HY-159934
    QI-18
    		Inhibitor
    QI-18 is a fibroblast activation protein (FAP) inhibitor with the IC50 of 0.50 nM, which is a 6.5-fold increase in potency over that of UAMC-1110 (HY-100684，IC50 of 3.25 nM). QI-18 can be used to synthesize high tumor selectivity and high dose radiotracers for the diagnosis and treatment of tumors.
    QI-18
  • HY-173319
    FAP-IN-5
    		Inhibitor
    FAP-IN-5 (Compound 4a) is an FAP inhibitor with an IC50 of 1.7 nM. FAP-IN-5 can be used in the research of tumor positron emission tomography (PET) imaging.
    FAP-IN-5
  • HY-174421
    FAPI-JNU
    		Ligand
    FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [68Ga]Ga or [177Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors).
    FAPI-JNU
  • HY-146181
    FSDD1I
    FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
    FSDD1I
  • HY-103323
    Fas C-Terminal Tripeptide
    		Inhibitor
    Fas C-Terminal Tripeptide is a C-terminal tripeptide of Fas. Fas C-Terminal Tripeptide shows the inhibitory effect on Fas/FAP-1 binding.
    Fas C-Terminal Tripeptide
  • HY-P3441
    3BP-4089
    3BP-4089 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-4089 is often coupled with radionuclides for tumor diagnosis and research.
    3BP-4089
  • HY-175330
    FAP-IN-6
    		Inhibitor
    FAP-IN-6 (Compound 21) is a selectivity FAP inhibitor with an IC50 of 13 pM. FAP-IN-6 has a high metabolic stability. FAP-IN-6 labeled with 18F can be used as a positron emission tomography (PET) tracer. FAP-IN-6 can be used for microenvironment of cancers research.
    FAP-IN-6
  • HY-175322
    FAPI-P8PN
    		Inhibitor
    FAPI-P8PN is a fibroblast activation protein (FAP) inhibitor (IC50=3.6 nM). FAPI-P8PN is promising for research of FAP-overexpressing solid tumors.
    FAPI-P8PN
  • HY-177083
    Faridoxorubicin
    		Substrate
    Faridoxorubicin (AVA-6000) is a prodrug targeting fibroblast activation protein α (FAPα). Faridoxorubicin releases active doxorubicin through FAPα-mediated cleavage, enhancing intratumoral drug exposure and reducing cardiac toxicity. Faridoxorubicin is promising for research of solid tumors (e.g., colorectal cancer liver metastasis).
    Faridoxorubicin
  • HY-178981
    FAP-IN-8
    		Inhibitor
    FAP-IN-8 is a FAP inhibitor. FAP-IN-8 has tumor penetrability. FAP-IN-8 is commonly used in cancer research.
    FAP-IN-8
  • HY-148361
    Fluorogen binding modulator-1
    Fluorogen binding modulator-1 (PubChem SID 125240934) is a fluorogen activating protein (FAP)-fluorogen binding modulator with -log EC50s of 6.61 and 6.37 for AM2.2-β2AR and AM2.2-GPR32, respectively.
    Fluorogen binding modulator-1
  • HY-175685
    FAP-IN-7
    		Inhibitor
    FAP-IN-7 (Compound 5b) is a FAP18F enhances tumor retention with high selectivity and favorable pharmacokinetics. FAP-IN-7 can be used as a radiotracer for PET imaging and radionuclide therapy of cancers research.
    FAP-IN-7
  • HY-175613
    DOTA-ALB-02
    		Ligand
    DOTA-ALB-02 is an albumin-bound FAP inhibitor (FAPI) ligand. DOTA-ALB-02 labeled with 177Lu has a high FAP-binding affinity and enhanced tumor uptake and retention with a significant tumor/nontarget ratio. DOTA-ALB-02 can be used for PET/CT and SPECT/CT imaging of cancers, especially late-stage cancers.
    DOTA-ALB-02
  • HY-170779
    DOTA-NI-FAPI-04
    		Inhibitor
    DOTA-NI-FAPI-04 is a FAP inhibitor (IC50 = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as 68Ga and 177Lu) through DOTA to produce radioactive probes ([68Ga]Ga/DOTA-NI-FAPI-04 and [177Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact.
    DOTA-NI-FAPI-04
  • HY-146182
    FSDD3I
    FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with 68Ga and 177Lu for single photon emission computed tomography (SPECT) imaging.
    FSDD3I
  • HY-175353
    TriOncoFAP-GlyPro-MMAE
    TriOncoFAP-GlyPro-MMAE is a small molecule drug conjugate (SMDC) targeting fibroblast activation protein (FAP) with an IC50 of 13 pmol/L. TriOncoFAP-GlyPro-MMAE combines a FAP-targeting ligand (TriOnco), a cleavable glycine-proline linker, and a cytotoxic payload (MMAE).
    TriOncoFAP-GlyPro-MMAE
  • HY-P3392
    Zilganersen
    Zilganersen (ION373) is a glial fibrillary acidic protein (GFAP) inhibitor, an antisense oligonucleotide. Zilganersen can be used in Alexander disease (AxD) research.
    Zilganersen
Cat. No. Product Name / Synonyms Application Reactivity